As a new-type foreign trade service provider driven by technological transformation and foreign trade business, HiSiaddi has established a "1+2+3+4=1" service system, and can supply Fmoc-8-amino-3,6-dioxaoctanoic acid (Semaglutide side chain intermediate) sourced from multiple well-known original manufacturers. As a research-and-development-oriented foreign trade enterprise, HiSiaddi has repeatedly resolved customized product demands for Fmoc-8-amino-3,6-dioxaoctanoic acid (Semaglutide side chain intermediate) through technological transformation cooperation with manufacturers and precise insight into market demands. Below is the case of HiSiaddi addressing customized production requirements for this product.
For inquiries regarding customized service solutions, please contact HiSiaddi customer service.
The client is Euro Peptide Pharma NV, a high-end biopharmaceutical enterprise headquartered in Brussels, Belgium. It focuses on R&D and commercial production of GLP-1 innovative drugs, supplying products to leading pharmaceutical companies and premium medical institutions across Europe, and strictly adheres to FDA, EMA, ICH Q7 and GMP quality specifications. The Fmoc-8-amino-3,6-dioxaoctanoic acid to be purchased this time is a key intermediate for Semaglutide side chains, a niche high-fine chemical product with an annual demand of 120kg delivered in multiple small batches, positioned as high-end pharmaceutical grade.
1. Purity Specifications: HPLC purity ≥99.8%, single known impurity ≤0.05%, total impurities ≤0.2%, far exceeding the general domestic industrial standard of 99.5%;
2. Residual Substance Control: Residual solvents in compliance with ICH Q3C standards, individual heavy metals (Pb, As, Cd, Hg) <0.1ppm, water content ≤100ppm;
3. Morphology & Specification: Customized high-crystallinity white powder with particle size D50=80~100μm, packed in 5kg vacuum aluminum foil bags with light-proof and moisture-proof protection;
4. Supporting Documentation: Full English COA, mass spectrometry/NMR spectra, analytical method validation reports, process validation documents, and support for EMA on-site audits;
5. Delivery Requirements: First batch of 30kg, complete customized development, production and delivery within 30 days with flexible batch-wise supply.
This intermediate features a long synthetic route and high purification difficulty. Local European suppliers suffer from scarce production capacity, exorbitant quotations and lead times exceeding 60 days. The client previously contacted 4 domestic chemical manufacturers, none of which could meet the full set of customization requirements: some manufacturers only achieved 99.5% purity and failed to control trace impurities; most enterprises lacked particle size regulation capacity and could not issue complete technical documents required for European pharmaceutical audits; meanwhile, small-batch customized orders were deprioritized in production scheduling, delaying project progress. The client entrusted HiSiaddi with full responsibility for customized development, process implementation and delivery assurance.
1. High Purification Difficulty: Homologues and degradation impurities with similar structures are generated during synthesis. Conventional recrystallization cannot achieve effective separation. Multi-stage refining processes with extremely low process tolerance are required to limit single impurities within 0.05%.
2. Precise Particle Size Regulation Barriers: Crystal formation is affected by multiple parameters including temperature, cooling rate, stirring speed and seed crystal addition. Exclusive crystallization formulas and precise parameter control are needed to stably maintain D50 within 80~100μm, which cannot be realized on ordinary production lines.
3. Stringent Trace Impurity Control: Pharmaceutical-grade products require trace-level control of heavy metals and residual solvents. Special treatment of production equipment, raw materials and pipelines is mandatory to avoid secondary contamination.
4. Mismatched Documentation System: Most domestic manufacturers only provide basic test reports, lacking ICH-standard method validation and process validation materials, making them unable to pass EMA audits.
5. High Demand for Flexible Production: The client’s small-batch, multi-batch supply model imposes stricter requirements on production line switching and batch consistency.
HiSiaddi set up a special team covering organic synthesis, purification, powder engineering, compliance documentation and supply chain management, screened domestic GMP factories with mature capacity for high-end peptide intermediate customization, signed non-disclosure agreements, and completed all customization tasks within 30 days following six stages: process development → lab-scale verification → pilot scale-up → mass production launch → supporting documentation → logistics delivery.
Production and purification processes were upgraded based on physical and chemical properties of the material:
· Optimized synthetic reaction conditions to reduce by-product formation at the source and lower impurity generation;
· Adopted a combined process of stepwise low-temperature recrystallization and deep column chromatography refining to replace single recrystallization, enabling targeted separation of homologues and degradation impurities;
· Added negative pressure high-temperature desolvation for finished products to thoroughly remove organic solvent residues, paired with chelating filtration systems to stabilize heavy metal ion levels below 0.08ppm.
After multiple rounds of parameter iteration, the HPLC purity of finished products stably reached 99.85%, single impurities ≤0.04%, total impurities ≤0.18%, and water content controlled at 85ppm, all exceeding client specifications.
· Fixed cooling curves of reaction kettles with gradient slow cooling to avoid over-rapid crystal growth or excessive fine powder generation;
· Quantitatively added special seed crystals and matched stirring speeds to precisely guide crystal formation;
· Deployed closed airflow screening equipment for finished products to remove oversized and ultrafine particles, finalizing particle size D50 at 92μm within the client’s required range with inter-batch particle size fluctuation less than 3μm.
The factory was required to deploy dedicated 316L stainless steel production lines with equipment cleaning validation completed before production. High-end pharmaceutical-grade raw materials were adopted, and crystallization, drying and packaging procedures were fully performed in Class 10,000 clean workshops to isolate dust, moisture and heavy metal contamination, ensuring long-term stability of trace impurity indicators.
In accordance with FDA, EMA and ICH Q7 specifications, a complete English technical document package was compiled, including batch-by-batch COA, HNMR/MS spectra, analytical method validation reports, process validation reports, cleaning validation reports and stability study data. All documents were formatted to meet European audit requirements with complete and traceable data.
Exclusive production schedules were set for small-batch orders with independent production and testing for each batch to guarantee batch consistency. The first 30kg batch was split into 3 separate production runs to mitigate scale-up risks.
Customized packaging consisting of double-layer vacuum aluminum foil bags plus moisture-proof outer packaging with built-in desiccants was adopted, fully sealed and light-shielded, marked with batch numbers, expiry dates and storage conditions to adapt to long-distance transportation and warehousing in Europe.
HiSiaddi assigned on-site quality control personnel to supervise production, sampling and testing throughout the process, synchronizing pre-test data of each batch to the client. After finished product inspection, temperature-controlled moisture-proof dedicated logistics were selected with full tracking of shipment status to guarantee intact delivery of goods.
1.
All Product Indicators Fully Met Specifications Test results of finished products: purity 99.85%, single impurity 0.04%, total impurities 0.18%; all heavy metals below 0.08ppm, water content 85ppm; particle size D50=92μm. All customized indicators satisfied and exceeded client requirements.
2.
3.
Smooth Acceptance of Delivery & Documentation The first 30kg batch was delivered in 28 days, 2 days ahead of the agreed timeline. The full set of English technical documents passed the client’s internal audit at one go, with completeness and standardization complying with EMA audit standards. After feeding materials into the client’s Semaglutide synthesis production line, stable reaction conversion rates were maintained without abnormal quality of downstream intermediates.
4.
5.
Optimized Cost & Supply Chain Compared with the client’s original European suppliers, overall procurement costs decreased by 30% and delivery lead time was cut by 50%. The stable flexible small-batch supply model perfectly matched the client’s R&D and mass production rhythm.
6.
7.
Deepened Cooperation The client’s technical team commented: “HiSiaddi thoroughly understands the customization requirements for high-end pharmaceutical intermediates. It not only overcomes technical bottlenecks including purity and particle size control, but also provides supporting technical documents fully aligned with European regulatory standards, making it a reliable long-term partner.”
8.
A three-year long-term supply agreement was signed between both parties, with annual procurement volume raised to 150kg. The client subsequently entrusted HiSiaddi with procurement and technical services for all high-end customized intermediates including multiple GLP-1 drug side chains and protected amino acids.
For overseas mid-to-high-end pharmaceutical enterprises purchasing niche high-end pharmaceutical intermediates such as Fmoc-8-amino-3,6-dioxaoctanoic acid, the five core customization challenges are ultra-high purity, trace impurity control, precise particle size adjustment, compliant documentation and flexible small-batch production. Overseas suppliers face tight production capacity and high costs, while ordinary domestic manufacturers are restricted by process, equipment and documentation systems, unable to undertake high-end customized orders and easily causing project delays for clients.
Relying on abundant resources of domestic high-end fine chemical factories, mature process development capabilities and extensive experience in European & American pharmaceutical compliance, HiSiaddi breaks through bottlenecks across the full industrial chain covering raw material synthesis, purification, powder regulation, production control, documentation compilation and logistics delivery, completing customized mass production within the agreed timeline. It not only resolves the client’s supply chain bottlenecks and reduces procurement costs, but also wins deep trust via professional technical and compliance services, facilitating the entry of domestic high-end pharmaceutical intermediates into high-end innovative drug supply chains in Europe.
For inquiries regarding customized service solutions, please contact HiSiaddi customer service.
+86-13120989737 
info@hisiaddi.com 
English
